Injectable Drug Delivery Market Analysis Till 2025:Baxter International Inc., BD, Gerresheimer, Pfizer, SCHOTT, Alkermes, Eli Lilly and Company, Sandoz, Terumo Medical Corporation, Teva Pharmaceuticals, Ypsomed AG, Bespak

Injectable Drug Delivery Market Analysis by Type (Injectable Drug Delivery Devices, Injectable Drug Delivery Formulation), Application (Hormonal Disorders, oncology, autoimmune diseases, orphan disease, other applications), Usage Pattern (Curative Care, Immunizations, Other Usage Pattern ), Mode Of Administration (Skin, Circulatory/ Muskoskeletal, Organs, Central Nervous System ), End User (Hospitals And Clinics, Home Healthcare Settings, Research Laboratories, Pharmaceutical And Biotechnological Companies, Other End Users), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, Direct Tender, Online Pharmacy),Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)

Downlaod| Free Sample Copy of Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-injectable-drug-delivery-market

Global injectable drug delivery market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025

By the help of SWOT analysis this report provides with a comprehensive insight about the Injectable Drug Delivery Market’s restrains and drivers all the keeping the report systematic and providing with the company profiles.

Key market players:

• Baxter International, Inc.,
• Becton Dickinson and Company,
• Gerresheimer AG,
• Pfizer, Inc.,
• Schott AG,
• Alkermes Plc.,
• Eli Lilly and Company,
• Sandoz,
• Terumo Corporation,
• Teva Pharmaceuticals Industries Ltd.
• Ypsomed,
• Bespak

Have Any Query? Ask Our Expert: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-injectable-drug-delivery-market

RISING CASES OF CHRONIC DISEASES

In recent years, the prevalence of chronic diseases (such as cancer, diabetes, hormonal disorder, and many others) across the globe has increased considerably over a period of time. The rapidly increasing aging population and the subsequent rise in chronic conditions are major factors driving the demand for and cost of healthcare. This increase in prevalence of chronic diseases has resulted in a significant increase in the demand for self-injectables as these devices are more convenient and safe to be use at home.

This increase in prevalence of chronic diseases can be attributed to unhealthy lifestyles, including excess consumption of alcohol and tobacco. The above-mentioned factors also increase health risks such as obesity, high blood pressure, and cholesterol, which in turn contribute towards the unprecedented rise in cases of chronic diseases.

Mention below is some of the statistics related to the chronic diseases.

• According to Centers for Disease Control and Prevention (CDC), stated that in America, each year 7 of 10 deaths are caused due to chronic diseases.

• According to World Health Organization, in 2016, 71 million people were affected globally by chronic hepatitis C infection.

• According to American Cancer Society, Inc., in 2016, it was estimated that in the U.S. around 1,685,210 new cases of cancer will be diagnosed and approximately 595,690 people will die due to this disease.

• According to World Federation of Hemophilia, in 2015, it was estimated that 187,183 people were suffering from Hemophilia globally.

RISING DEMAND OF SELF-INJECTION DEVICES

Self-injection devices are a combination of automatic injection systems with audio-visual guides for surgeries; this includes safety syringes and hidden needles, among others. It has also emerged as one of the fastest growing areas for unit dose medication in order to minimize drug waste and increase product lifespan. As patients are able to self-administer injectable drugs at their home instead of the regular visits to the hospital it improves safety and patient compliance, thus, making the injections easy, safe and convenient. It reduces anxiety eliminating needle phobia through various self-injection devices like auto injectors, pen injectors, needle-free injectors and wearable injectors. These self-injection devices imparts the drug faster and has better reproducibility as compared to invasive drug delivery systems and hence enhance bioavailability when compared with invasive drug delivery systems.

With the existence of a large number of injectable drugs and higher demand for self-injectables from patients, many pharmaceutical players are introducing innovative self-administration therapies. In February 2013, Novo Nordisk launched NovoSeven (Recombinant factor VIIa) with a prefilled syringe system that is used for the treatment of hemophilia. Also, Autoject 2 is an automated injection device of Owen Mumford Company enabling effective drug delivery at a touch of a button to encourage patient’s self-reliance by concealing the needle in order to guard against accidental injury.

To Understand Complete Table Of Content, Tables And Figures @ https://databridgemarketresearch.com/toc/?dbmr=global-injectable-drug-delivery-market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:
Sopan Gedam
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.